BioSpace News Archive

Pharnext SA announced that the U.S. Food and Drug Administration has granted Fast Track designation for the development of PXT3003 for the treatment of patients with Charcot-Marie-Tooth disease Type 1A.

Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, is pleased to announce that ModernaTX, Inc. has exercised its option to enter into an exclusive licensing agreement with respect to certain Affimers against a potential therapeutic target that has been part of an ongoing research collaboration between the two companies.

Ultragenyx Pharmaceutical Inc. announced the appointment of Shehnaaz Suliman, M.D., to the company’s Board of Directors, effective January 30, 2019.

Biometric screening gives early warning on health, improves productivity, morale

Company Also Awarded Best in KLAS for Vue PACS in the Middle East/Africa

Evonik has completed the conceptual and basic engineering phase for building its new polyamide 12 (PA12) production complex on schedule by the end of the past year and has now entered the project implementation phase.

Paras Biopharmaceuticals Finland Oy announced the achievement of a major milestone – the successful development of biologically active Romiplostim production technology.

Scarab Genomics LLC and Theraly Fibrosis Inc. announced that they have entered into a license agreement to allow Theraly Fibrosis to fully exploit Scarab Genomics’ technology for the production of a protein for its core therapeutic program.

Argenx, based in Breda, the Netherlands, and Halozyme Therapeutics, headquartered in San Diego, CA, signed a global collaboration and license deal that lets Argenx use Halozyme’s Enhanze drug delivery technology to develop multiple products.

As a valued member of our BioSpace community, we are eager to hear more from you and other readers in 2019. What are the unique benefits your life sciences employer offers?